Use of adjuvant regimens with single-cytotoxic agents among women with stage II-III HER2-positive breast cancer. Key predictive features and their contribution to Pathologic Complete Response (pCR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback